Conference Correspondent
A retrospective analysis of ICARIA-MM and TCD14079 studies shows adding isatuximab to pomalidomide-dexamethasone improved progression-free survival and increased rates of overall response and very good partial response or better in patients with gain(1q21). Read More ›
Adding isatuximab to pomalidomide-dexamethasone treatment in RRMM patients with preexisting plasmacytomas resulted in improved median progression-free survival and rates of overall response and very good partial response with a manageable safety profile. Read More ›
Addition of daratumumab to ixazomib/dexamethasone in second-line post-lenalidomide relapsed multiple myeloma (phase 1 portion of the ongoing DARIA study) resulted in a >70% overall response rate. Read More ›
This pivotal trial (OPTIMISMM) subgroup analysis supports use of pomalidomide, bortezomib, and low-dose dexamethasone for lenalidomide-refractory patients regardless of age, prior stem-cell transplant status, or presence of high-risk cytogenetic abnormalities. Read More ›
An observational study of ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma in French centers (REMIX) further defined the patient and disease characteristics and safety profile with this regimen; efficacy data are still maturing. Read More ›
An ongoing study of venetoclax plus daratumumab and dexamethasone ± bortezomib in patients with relapsed/refractory multiple myeloma demonstrated tolerable safety and clinically meaningful overall response rate (92%-96%), particularly among those with t(11;14). Read More ›
In patients with multiple myeloma who undergo frontline optimized induction followed by ASCT, MRD assessment and clinical response time kinetics were predictive of unsustained complete remission, based on a subgroup analysis of PETHEMA/GEM2012MENOS65. Read More ›
Addition of venetoclax to bortezomib/dexamethasone in relapsed/refractory multiple myeloma patients (BELLINI phase 3 study) improves progression-free survival, but also results in higher mortality, with t(11;14) or BCL2high gene expression patients benefiting most. Read More ›
In the DREAMM-2 study of belantamab mafodotin in heavily pretreated relapsed/refractory multiple myeloma patients, comparable overall response rates (~30%) were observed between patients who had 3 to 6 prior therapies and those with ≥7. Read More ›
Melflufen/dexamethasone demonstrated meaningful activity and manageable safety profile in patients with relapsed/refractory multiple myeloma who had ≥2 prior lines of therapy and were also refractory to pomalidomide and/or an anti-CD38 monoclonal antibody. Read More ›